Listed by the USPTO as SCHLIENTZ, LEAH H
Tech Center 1600 • Art Units: 1618
This examiner grants 42% of resolved cases
SCHLIENTZ, LEAH H has 603 resolved cases and an allowance rate of 41.8%. The median time to allowance is 1548 days. Interviews correspond to a 38.7% lift in the allowance rate, making direct examiner engagement a significant consideration for applicants facing difficult examination. The timing measure also supports planning for a prolonged prosecution path where claim changes and evidence may require repeated attention.
The listed companies are Alume Biosciences Inc., Monopar Therapeutics Inc., and Nanjing Leapsonics Technology Co. Ltd. The listed firms are BOZICEVIC, FIELD & FRANCIS LLP, GOODWIN PROCTER LLP, and Lathrop GPM LLP. These organizations identify the technology and counsel settings represented in the resolved docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18026300 | COMPOSITIONS INCLUDING MAGNETIC NANOPARTICLES AND METHODS OF USING AND MAKING THE SAME | Final Rejection | University of Florida Research Foundation, Inc. |
| 17742390 | COMPOUND AND FLUORESCENTLY LABELED BIOLOGICAL SUBSTANCE USING THE SAME | Final Rejection | FUJIFILM Corporation |
| 17358544 | Methods for Cell Labeling and Medical Imaging | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18257974 | ISOCYCLOSERAM FORMULATION | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18381930 | POLYMERIC PERFLUOROCARBON NANOEMULSIONS FOR ULTRASONIC DRUG UNCAGING | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17588458 | MAGNETIC RESONANCE CONTRAST AGENTS AND METHODS THEREOF | Final Rejection | THE TEXAS A&M UNIVERSITY SYSTEM |
| 18607920 | SYSTEMS AND METHODS FOR MONITORING OF DELIVERY OF LABEL-FREE DRUGS | Non-Final OA | City University of Hong Kong |
| 17632438 | ADDITIONAL MASS TAG POLYMERS FOR MASS CYTOMETRY | Final Rejection | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO |
| 17253307 | TRIAZAMACROCYCLE-DERIVED CHELATOR COMPOSITIONS FOR COORDINATION OF IMAGING AND THERAPY METAL IONS AND METHODS OF USING SAME | Final Rejection | The Research Foundation for The State University of New York |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
| 18040011 | COMPOSITION COMPRISING A RAPALOG AND A RADIOLABELLED GASTRIN ANALOGUE, IN PARTICULAR FOR USE IN THE TREATMENT AND/OR DIAGNOSIS OF CCKB RECEPTOR POSITIVE CANCER OR TUMORS | Final Rejection | Paul Scherrer Institut |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy41.8% of resolved applications examined by Leah H Schlientz were allowed (603 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +38.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Leah H Schlientz took 1,548 days on average from filing to allowance.
Leah H Schlientz examines applications in Art Unit 1618 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
